Barclays PLC Eq Rx, Inc. Transaction History

Barclays PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	SELL	$1.66 - $2.31 $84,927 - $118,181	-51,161 Reduced 13.29%	333,686 $741,000
Q2 2023 Aug 03, 2023	SELL	$1.61 - $1.96 $96,562 - $117,554	-59,977 Reduced 13.48%	384,847 $716,000
Q1 2023 May 04, 2023	SELL	$1.8 - $2.83 $396,639 - $623,604	-220,355 Reduced 33.13%	444,824 $863,000
Q4 2022 Feb 13, 2023	BUY	$2.05 - $5.5 $605,961 - $1.63 Million	295,591 Added 79.98%	665,179 $1.64 Million
Q3 2022 Nov 03, 2022	BUY	$0.94 - $5.99 $336,193 - $2.14 Million	357,653 Added 2996.67%	369,588 $1.83 Million
Q2 2022 Aug 12, 2022	SELL	$3.2 - $5.69 $59,552 - $105,890	-18,610 Reduced 60.93%	11,935 $56,000
Q1 2022 May 16, 2022	BUY	$2.8 - $7.39 $85,526 - $225,727	30,545 New	30,545 $126,000

67.8M

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.